These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36368227)

  • 1. Dravet syndrome: Advances in etiology, clinical presentation, and treatment.
    He Z; Li Y; Zhao X; Li B
    Epilepsy Res; 2022 Dec; 188():107041. PubMed ID: 36368227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dravet Syndrome: Diagnosis and Long-Term Course.
    Connolly MB
    Can J Neurol Sci; 2016 Jun; 43 Suppl 3():S3-8. PubMed ID: 27264139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dravet syndrome: a genetic epileptic disorder.
    Akiyama M; Kobayashi K; Ohtsuka Y
    Acta Med Okayama; 2012; 66(5):369-76. PubMed ID: 23093055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-span characterization of epilepsy and comorbidities in Dravet syndrome mice carrying a targeted deletion of exon 1 of the Scn1a gene.
    Gerbatin RR; Augusto J; Boutouil H; Reschke CR; Henshall DC
    Exp Neurol; 2022 Aug; 354():114090. PubMed ID: 35487274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCN1A-related phenotypes: Epilepsy and beyond.
    Scheffer IE; Nabbout R
    Epilepsia; 2019 Dec; 60 Suppl 3():S17-S24. PubMed ID: 31904117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myoclonic Absence Seizures in Dravet Syndrome.
    Myers KA; Scheffer IE
    Pediatr Neurol; 2017 May; 70():67-69. PubMed ID: 28233668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dravet syndrome, what is new?
    Al-Baradie RS
    Neurosciences (Riyadh); 2013 Jan; 18(1):11-7. PubMed ID: 23291792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
    Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
    Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel rat model of Dravet syndrome recapitulates clinical hallmarks.
    Li M; Yang L; Qian W; Ray S; Lu Z; Liu T; Zou YY; Naumann RK; Wang H
    Neurobiol Dis; 2023 Aug; 184():106193. PubMed ID: 37295561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From genotype to phenotype in Dravet disease.
    Gataullina S; Dulac O
    Seizure; 2017 Jan; 44():58-64. PubMed ID: 27817982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.
    Schutte RJ; Schutte SS; Algara J; Barragan EV; Gilligan J; Staber C; Savva YA; Smith MA; Reenan R; O'Dowd DK
    J Neurophysiol; 2014 Aug; 112(4):903-12. PubMed ID: 24805083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program.
    Pernici CD; Mensah JA; Dahle EJ; Johnson KJ; Handy L; Buxton L; Smith MD; West PJ; Metcalf CS; Wilcox KS
    Epilepsia; 2021 Jul; 62(7):1665-1676. PubMed ID: 34002394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome.
    Wengert ER; Wagley PK; Strohm SM; Reza N; Wenker IC; Gaykema RP; Christiansen A; Liau G; Patel MK
    Brain Res; 2022 Jan; 1775():147743. PubMed ID: 34843701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early clinical features and diagnosis of Dravet syndrome in 138 Chinese patients with SCN1A mutations.
    Xu X; Zhang Y; Sun H; Liu X; Yang X; Xiong H; Jiang Y; Bao X; Wang S; Yang Z; Wu Y; Qin J; Lin Q; Wu X
    Brain Dev; 2014 Sep; 36(8):676-81. PubMed ID: 24168886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining Dravet syndrome: An essential pre-requisite for precision medicine trials.
    Li W; Schneider AL; Scheffer IE
    Epilepsia; 2021 Sep; 62(9):2205-2217. PubMed ID: 34338318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding neurodevelopmental trajectories and behavioral profiles in SCN1A-related epilepsy syndromes.
    Postma A; Minderhoud CA; Otte WM; Jansen FE; Gunning WB; Verhoeven JS; Jongmans MJ; Zinkstok JR; Brilstra EH
    Epilepsy Behav; 2024 May; 154():109726. PubMed ID: 38513571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome.
    Niibori Y; Lee SJ; Minassian BA; Hampson DR
    Hum Gene Ther; 2020 Mar; 31(5-6):339-351. PubMed ID: 31830809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dravet syndrome and its mimics: Beyond SCN1A.
    Steel D; Symonds JD; Zuberi SM; Brunklaus A
    Epilepsia; 2017 Nov; 58(11):1807-1816. PubMed ID: 28880996
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.